Collectively, this body of work provides the mechanistic foundation for how hypoxia drives hMENA AS in breast cancer (Figure 8), and suggests the relevance of hypoxia-driven TGF-β signaling and its multifaceted aspects in the potential development of novel anti-EMT therapeutic approaches. This evidence concerns the gene TGFB1 and breast carcinoma.